A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

@article{Rosell1994ART,
  title={A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.},
  author={Rafael Rosell and José Gomez-Codina and Carlos Camps and Jos{\'e} Antonio Maestre and Jose Padille and Antonio Cant{\'o} and Jos{\'e} Lu{\'i}s Mate and S. Li and Jorge Roig and {\'A}ngel Olaz{\'a}bal},
  journal={The New England journal of medicine},
  year={1994},
  volume={330 3},
  pages={
          153-8
        }
}
BACKGROUND The efficacy of surgery for patients with non-small-cell lung cancer is limited, although recent studies suggest that preoperative chemotherapy may improve survival. We conducted a randomized trial to examine the possible benefit of preoperative chemotherapy and surgery for the treatment of patients with non-small-cell lung cancer. METHODS We studied 60 patients (59 men and 1 woman) with stage IIIA non-small-cell lung cancer. The patients were randomly assigned to receive either… 

Figures and Tables from this paper

Neoadjuvant chemotherapy in stage Illa non-small cell lung cancer LEARNING POINTS *

Preoperative chemotherapy increases the median survival in patients with non-small cell lung cancer, and the prevalence of mutated K-ras oncogenes was 15 percent among the patients receiving preoperative chemotherapy and 42 percent among those treated with surgery alone.

Long-term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non-small cell lung cancer

Preoperative chemotherapy did not show benefits in OS and PFS for stage I–IIIA NSCLC patients, and the survival rate was higher for patients who had clinical remission after preoperative chemotherapy, but the differences did not reach statistical significance.

Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

  • E. FelipR. Rosell B. Massuti
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
In early-stage patients, no statistically significant differences in disease-free survival were found with the addition of preoperative or adjuvant chemotherapy to surgery in this phase III trial, in which the treatment decision was made before surgery.

Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

  • D. WallerM. Peake S. Spiro
  • Medicine
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • 2004

A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).

This randomized trial to compare induction chemotherapy (cisplatin and vindesine) followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer did not demonstrate a survival difference between the groups, although this may have been because the statistical power was limited.

Chemotherapy in resectable non-small cell lung cancer

  • E. Felip
  • Medicine
    Revista de Oncología
  • 2004
Combined modality treatment in NSCLC continues to evolve and is a subject of ongoing research, some data suggest that induction chemotherapy in stage I-II is feasible, does not appear to compromise surgery and yields high response rates.

Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer.

In this trial, the chemotherapy regimen was sufficiently toxic to have had a lower completion rate of prescribed therapy in the CSCR arm than in the RSR arm, and overall survival did not differ between the two treatment arms.

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy, and radiotherapy should be considered the preferred locoregional treatment for these patients.
...

References

SHOWING 1-10 OF 59 REFERENCES

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

This clinical trial strengthens the validity of using perioperative chemotherapy in the management of patients with resectable stage IIIA non-small-cell lung cancer by suggesting that survival is improved when compared with treatment by surgery alone.

Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study.

The results suggest that patients with NSCLC at pathologic stage I who have undergone radical surgery benefit from adjuvant chemotherapy.

The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group.

  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1988
Analysis of sites of recurrence showed a significant decrease in distant metastases in the chemotherapy arm and a 14% difference in survival rate favoring the chemotherapy side 1 year after randomization.

Adjuvant cancer chemotherapy after resection of carcinoma of the lung

A prospective randomized trial was conducted in an attempt to discern the value of prolonged intermittent courses of adjuvant cancer chemotherapy after a successful curative resection of a carcinoma of the lung in men.

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

The results observed in a large, randomized study that compared the effects of radiotherapy alone (the standard therapy) with those of a combination of radi therapy and chemotherapy in nonresectable squamous cell and large-cell lung carcinoma showed local control was poor in both groups and remained the major problem.

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.

  • R. BurkesR. Ginsberg J. Cooper
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
It is concluded that MVP is an effective but toxic chemotherapeutic regimen for limited NSCLC; the median survival seems to be prolonged; and the role of induction chemotherapy followed by surgery in stage IIIA N2 NSCLc requires a phase III randomized trial to compare it with other treatment modalities.

Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma.

A phase II study of simultaneous continuous infusion 5-fluorouracil and split-course radiation with or without surgery has shown possible improvement in median survival compared with that observed in trials of radiation alone.

Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer.

The patients with chemotherapy, chest irradiation, and surgical resection had a low incidence of local in-chest failure, but distant failure was still a major problem, and there were no statistically significant survival differences between patients not having thoracotomy and those who hadThoracotomy.
...